Drugs / mRNA-1365
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05743881 | Feb 2023 → Aug 2029 expected | respiratory syncytial virus infectious disease | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05743881 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)” NCT05743881 ↗ |
| Route | Intramuscular | “Participants will receive mRNA-1365 vaccine by IM injection” NCT05743881 ↗ |